By targeting the EGFR-dependent cancer cell proliferation and the VEGFR-2-dependent tumour angiogenesis pathways, vandetanib offers the potential advantages of blocking two key pathways in different tumour types, namely cell proliferation and angiogenesis. This evidence concerns the gene KDR and cancer.